Tempus
AI-powered precision oncology platform analyzing clinical and molecular data for personalized cancer care.
Tempus is a top-tier platform for oncologists and researchers seeking AI-powered insights from clinical and genomic data. Its vast data library and real-world evidence capabilities are unmatched, but the lack of transparent pricing and enterprise-only model make it inaccessible for small practices. Consider Foundation Medicine for genomic profiling or Flatiron Health for real-world evidence if budget is a concern.
- Oncologists seeking AI-powered treatment recommendations from genomic and clinical data
- Pharmaceutical companies requiring real-world evidence for drug development
- Cancer researchers needing large-scale de-identified patient data analytics
- Academic medical centers integrating molecular profiling with clinical outcomes
- Small independent clinics without budget for enterprise-scale AI platform
- Patients seeking direct-to-consumer genetic testing
- Healthcare providers looking for a simple single-gene test
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Tempus if you are a small independent clinic with a limited budget, need transparent pricing upfront, or require a simple single-gene test rather than a comprehensive genomic profiling platform.
Enterprise-only pricing with no public tiers means you must contact sales for a quote, making budget planning difficult for smaller organizations.
Tempus targets large cancer centers and pharmaceutical companies with enterprise-level budgets. For smaller practices, Foundation Medicine offers more transparent per-test genomic profiling; Flatiron Health provides real-world evidence at a potentially lower enterprise tier. Tempus's custom pricing is opaque, limiting cost comparison.
In short
Tempus — AI-powered precision oncology platform analyzing clinical and molecular data for personalized cancer care. Best for Oncologists seeking AI-powered treatment recommendations from genomic and clinical data, Pharmaceutical companies requiring real-world evidence for drug development, Cancer researchers needing large-scale de-identified patient data analytics. Contact Sales pricing.
Viability Score
How likely is Tempus to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Key Features
- AI-driven clinical and molecular data analysis
- Tempus xT DNA/RNA sequencing panel (648 genes)
- Tempus LENS cloud-based analytics tool
- Real-world evidence generation
- De-identified patient record aggregation (7M+ records)
- Genomic alteration detection
- Treatment outcome prediction
- Clinical trial matching
- Multimodal data integration (genomic, clinical, imaging)
- Physician decision support
- Tempus PRO AI-assisted notetaking for neurologists
- ECG-AI for cardiovascular patient identification
- Tempus Pixel radiology therapy response evaluation
- Pharmaceutical research data access
About Tempus
Tempus is a health technology company that leverages artificial intelligence and a vast library of clinical and molecular data to enable personalized cancer care. By analyzing de-identified patient records and genomic sequencing data, Tempus provides actionable insights to physicians, helping them make more informed treatment decisions. The platform offers a suite of products including Tempus xT, a DNA/RNA sequencing panel that detects relevant genomic alterations, and Tempus LENS, a cloud-based analytics tool for real-world evidence generation. With over 7 million de-identified clinical records and a network of over 8,000 clinicians, Tempus empowers researchers and healthcare providers with data-driven tools. Its partnerships with pharmaceutical companies and academic institutions accelerate clinical trials and drug discovery. Unlike traditional diagnostics, Tempus' AI-driven approach integrates multimodal data for a comprehensive view of a patient's cancer, positioning it as a leader in precision oncology.
Behind the Verdict
Tempus stands out for its massive integrated dataset combining genomic, clinical, and imaging data, which fuels AI models that can identify treatment options and clinical trial matches. The proprietary Tempus xT panel covers 648 genes, and Tempus Pixel provides radiology AI. Strengths include multimodal data integration, real-world evidence for pharma, and a growing network of over 8,000 clinicians. Weaknesses include enterprise-only pricing (no transparent tiers), complexity requiring IT support, and primary focus on oncology, limiting broader applicability. It's best suited for large cancer centers and pharmaceutical R&D, not small clinics or direct-to-consumer use.
Researching Tempus? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Tempus actually fits — and what changes day-one when you adopt it.
You order Tempus xT genomic profiling for a new lung cancer patient. The AI analyzes the tumor's DNA/RNA alterations and cross-references 7M+ records to suggest targeted therapies and clinical trials. Within 14 days, you receive a report with prioritized treatment options.
Outcome: Faster, data-driven treatment decisions with matching to the most relevant clinical trials, potentially improving patient outcomes.
You use Tempus LENS to query de-identified real-world data to understand therapy response patterns in a specific biomarker-defined population. The platform generates a cohort analysis with treatment timelines and outcomes, accelerating study design.
Outcome: Reduced time to generate real-world evidence for regulatory submissions or trial protocol design, using a dataset of over 7M records.
Use Cases
- Identifying targeted therapies for cancer patients based on genomic profiling
- Matching patients to clinical trials using AI and real-world data
- Accelerating drug discovery with real-world evidence for pharma
- Closing care gaps in oncology through AI-enabled analytics
- Supporting neurologists with AI-assisted notetaking (Tempus PRO)
- Identifying underdiagnosed cardiovascular patients using ECG-AI
- Evaluating therapy response in radiology with Tempus Pixel
- Providing de-identified data access for research
Models Under the Hood
as of 2026-07-06
Limitations
- Pricing is enterprise-only and not publicly disclosed, making it inaccessible for small practices.
- The platform's complexity may require dedicated IT support for integration.
- It is primarily focused on oncology, though expanding into other areas.
- Direct-to-consumer access is not available.
as of 2026-07-02
12-month cost
Project the real annual outlay, including the implied monthly cost when only an annual tier is published.
Vendor list price only. Add-on usage, seat overages, and contract minimums are surfaced under Hidden costs & gotchas.
Plans compared
For each published Tempus tier: who it actually fits, and what it adds vs. the previous tier. Cross-reference the cost calculator above for projected annual outlay.
Clinical
Custom
Ideal for
Large cancer centers and hospitals that require comprehensive genomic profiling with AI-driven treatment insights and clinical trial matching for their patients.
What this tier adds
Starting tier focused on patient care: includes Tempus xT genomic profiling, AI treatment insights, and clinical trial matching.
Research
Custom
Ideal for
Pharmaceutical companies, academic researchers, and CROs needing access to de-identified real-world data and AI analytics for drug development and evidence generation.
What this tier adds
Adds de-identified data access, AI model building tools, and real-world evidence generation; tailored for research and development use cases.
Where the pricing makes sense
The company stage and team size where Tempus's pricing actually pencils out — and where peers do it cheaper.
Tempus targets large cancer centers and pharmaceutical companies with enterprise-level budgets. For smaller practices, Foundation Medicine offers more transparent per-test genomic profiling; Flatiron Health provides real-world evidence at a potentially lower enterprise tier. Tempus's custom pricing is opaque, limiting cost comparison.
Setup time & first value
How long it actually takes to get something useful out of Tempus — broken out by persona, not the marketing-page minute.
For an oncologist at a partnered institution, initial setup includes integrating EHR systems and ordering the Tempus xT test; first results appear within 7–14 days. Full platform adoption (LENS, Pixel) may take several weeks for IT integration and staff training. Enterprise deployment typically involves a multi-month onboarding process.
Switching to or from Tempus
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From Foundation Medicine: Upload previous genomic reports and establish a data integration pipeline with Tempus LENS for broader analytics
- →From Caris Life Sciences: Request a data transfer of historical molecular profiles and begin using Tempus xT for new cases
- →From in-house databases: Use Tempus's API and FHIR integration to migrate existing clinical and genomic data
- ↗To Foundation Medicine: Export Tempus xT reports as PDFs or structured data; contact Foundation Medicine for data format compatibility
- ↗To Flatiron Health: Request a de-identified data dump from Tempus LENS (subject to data use agreements) to seed Flatiron's OncoEMR
- ↗To internal database: Use Tempus API to export all patient records and genomic outputs in standard formats (e.g., VCF, HL7)
Resources & Guides
Official links
Tools that pair well with Tempus
Common stack mates teams adopt alongside Tempus, with the specific reason each pairing earns its keep.
Alternatives to Tempus
View allFlatiron Health
Real-world oncology data + AI to accelerate cancer insights and decisions.
Recursion
AI-driven drug discovery platform using phenomics and massive biological datasets
Nimbus Therapeutics
AI-driven small molecule drug discovery for selective oncology and immunology
Frequently Asked Questions
Categories
Best-of guides
Topics
Used Tempus? Help shape our editorial sentiment research.